Developer docs
API playgroundTry for free, no card

Search company profiles

MDNA Life Sciences

Full company profile

uuid0008x7u

Namestring
MDNA Life Sciences
Company typeenum
Private
Founded yearint
2014
Descriptiontext

MDNA Life Sciences is a privately held biotechnology company founded in 2014 and headquartered in West Palm Beach, Florida. The company operates with a lean team of 1-10 employees and maintains a functional executive structure comprising a CEO, CFO, Chief Scientific Officer, Chief Business Officer, and Chief Data Officer, suggesting it is organized to pursue scientific research and development activities in the life sciences domain.

The firm's specific product portfolio, underlying technology platform, scientific pipeline, and intellectual property base are not disclosed in the available data. The company's public website currently renders only a verification/loading interface rather than substantive company information, and no patents, publications, partnerships, regulatory milestones, or product launches are documented. The presence of a CSO indicates active scientific direction, while the CDO role signals some emphasis on data-related capabilities, though specific applications are not described.

With no disclosed customers, pricing model, revenue figures, funding history, or commercialization milestones in the supplied material, MDNA Life Sciences appears to be at an early or pre-commercial stage. Its business model, target indications, go-to-market strategy, and revenue mechanics cannot be characterized from the evidence available, which is a material limitation for any analytical assessment.

Short descriptiontext

MDNA Life Sciences is a privately held biotechnology company founded in 2014 and based in West Palm Beach, Florida, operating with a 1-10 employee team. The company maintains scientific, business, and data leadership functions, though its specific products, pipeline, and commercialization stage are not publicly disclosed.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWest Palm Beach, United States
HQ citystring
West Palm Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
mitochondrial DNA diagnostics, molecular biomarker assays, genetic diagnostic research, precision medicine biotech, life sciences laboratory services
Industry2 codes
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics and Biomarker Discovery
Social media profiles1 record
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

MDNA Life Sciences is a biotechnology company developing molecular diagnostic products and biomarker discovery services centered on mitochondrial DNA (mtDNA) analysis. The firm applies proprietary genetic and molecular biology techniques to identify mtDNA-based biomarkers for disease detection and research applications, serving life sciences research and clinical diagnostic markets.

Differentiator
Functional benefit
Problem solved
Product and service2 records
1Mitochondrial DNA Biomarker Discovery Services
CategoryMolecular Diagnostics and Biomarker Discovery
Description

Research services that identify and validate mitochondrial DNA-based biomarkers for disease detection, intended for biotechnology, pharmaceutical, and academic research buyers requiring specialized mtDNA analysis.

2Molecular Diagnostic Assay Development
CategoryMolecular Diagnostics
Description

Custom and proprietary development of molecular diagnostic assays based on mitochondrial DNA biomarkers, designed for research use and downstream clinical diagnostic applications.

No data
Peers10 records
TypeBroad incumbent
Description

Myriad is a major molecular diagnostics company offering germline and somatic genetic tests across oncology, women's health, and mental health. It is a relevant incumbent benchmark for any small molecular DNA-focused biotech like MDNA.

TypeDirect peer
Description

Natera is a DNA-based diagnostics company specializing in cell-free DNA testing across reproductive health, oncology, and organ transplant monitoring. Closely comparable to MDNA given the molecular DNA focus and clinical diagnostic positioning.

TypeBroad incumbent
Description

Guardant Health is a leading precision oncology liquid biopsy company using circulating tumor DNA for therapy selection and monitoring. Comparable as a molecular DNA diagnostics peer with established clinical and biopharma channels.

TypeBroad incumbent
Description

Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of tumors using DNA sequencing to inform oncology treatment. Relevant incumbent comparator for a molecular DNA-based diagnostics company.

TypeDirect peer
Description

NeoGenomics operates oncology-focused clinical laboratories providing molecular and genetic testing services to hospitals, oncologists, and researchers. Comparable as a direct molecular diagnostics services peer.

TypeDirect peer
Description

Veracyte is a genomic diagnostics company developing tests that resolve diagnostic ambiguity in cancer and other diseases using RNA and DNA-based methods. Direct comparator in genomic clinical diagnostics.

TypeEmerging player
Description

Personalis is a smaller molecular diagnostics company focused on immuno-oncology and tumor molecular profiling. Comparable as a peer-scale molecular DNA diagnostics player with biopharma services revenue.

TypeBroad incumbent
Description

Invitae is a genetics company offering genetic testing across multiple disease areas, now operating under Chapter 11 with restructured scope. Relevant as a historical molecular DNA diagnostics comparator despite current distress.

TypeEmerging player
Description

Caris provides molecular profiling services including DNA and RNA sequencing for oncology and biopharma partners. Comparable as a mid-sized molecular profiling peer with services + biopharma channel model.

TypeBroad incumbent
Description

Exact Sciences is a major molecular diagnostics company best known for Cologuard, now expanding into multi-cancer detection and oncology. Relevant broad incumbent comparator for any molecular DNA diagnostics business.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MDNA Life Sciences

Molecular Diagnostics and Biomarker Discoverymdnalifesciences.com

MDNA Life Sciences is a privately held biotechnology company founded in 2014 and based in West Palm Beach, Florida, operating with a 1-10 employee team. The company maintains scientific, business, and data leadership functions, though its specific products, pipeline, and commercialization stage are not publicly disclosed.

What MDNA Life Sciences does

MDNA Life Sciences is a privately held biotechnology company founded in 2014 and headquartered in West Palm Beach, Florida. The company operates with a lean team of 1-10 employees and maintains a functional executive structure comprising a CEO, CFO, Chief Scientific Officer, Chief Business Officer, and Chief Data Officer, suggesting it is organized to pursue scientific research and development activities in the life sciences domain.

The firm's specific product portfolio, underlying technology platform, scientific pipeline, and intellectual property base are not disclosed in the available data. The company's public website currently renders only a verification/loading interface rather than substantive company information, and no patents, publications, partnerships, regulatory milestones, or product launches are documented. The presence of a CSO indicates active scientific direction, while the CDO role signals some emphasis on data-related capabilities, though specific applications are not described.

With no disclosed customers, pricing model, revenue figures, funding history, or commercialization milestones in the supplied material, MDNA Life Sciences appears to be at an early or pre-commercial stage. Its business model, target indications, go-to-market strategy, and revenue mechanics cannot be characterized from the evidence available, which is a material limitation for any analytical assessment.

MDNA Life Sciences firmographics

Firmographics
Name
MDNA Life Sciences
Website
https://mdnalifesciences.com
Company type
Private
Founded year
2014
Headcount range
1–10 employees
Short description
MDNA Life Sciences is a privately held biotechnology company founded in 2014 and based in West Palm Beach, Florida, operating with a 1-10 employee team. The company maintains scientific, business, and data leadership functions, though its specific products, pipeline, and commercialization stage are not publicly disclosed.
Ownership category
akta.pro rank

MDNA Life Sciences industry classification

Industry
Product category
Molecular Diagnostics and Biomarker Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAGAJAC
Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

  • Mitochondrial DNA diagnostics
  • Molecular biomarker assays
  • Genetic diagnostic research
  • Precision medicine biotech
  • Life sciences laboratory services

Where MDNA Life Sciences is headquartered

Location

Headquarters

HQ city
West Palm Beach
HQ country
United States
HQ region
North America

Markets served

MDNA Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

MDNA Life Sciences product offering

Product offering

Core offering

MDNA Life Sciences is a biotechnology company developing molecular diagnostic products and biomarker discovery services centered on mitochondrial DNA (mtDNA) analysis. The firm applies proprietary genetic and molecular biology techniques to identify mtDNA-based biomarkers for disease detection and research applications, serving life sciences research and clinical diagnostic markets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Mitochondrial DNA Biomarker Discovery Services Research services that identify and validate mitochondrial DNA-based biomarkers for disease detection, intended for biotechnology, pharmaceutical, and academic research buyers requiring specialized mtDNA analysis.
  • Molecular Diagnostic Assay Development Custom and proprietary development of molecular diagnostic assays based on mitochondrial DNA biomarkers, designed for research use and downstream clinical diagnostic applications.

Companies that use MDNA Life Sciences

Customer profile

Ideal customer profiles1 record

MDNA Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

MDNA Life Sciences competitors and assessment

Company assessment

Broad incumbents

  • Myriad Genetics: Myriad is a major molecular diagnostics company offering germline and somatic genetic tests across oncology, women's health, and mental health. It is a relevant incumbent benchmark for any small molecular DNA-focused biotech like MDNA.
  • Guardant Health: Guardant Health is a leading precision oncology liquid biopsy company using circulating tumor DNA for therapy selection and monitoring. Comparable as a molecular DNA diagnostics peer with established clinical and biopharma channels.
  • Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of tumors using DNA sequencing to inform oncology treatment. Relevant incumbent comparator for a molecular DNA-based diagnostics company.
  • Invitae: Invitae is a genetics company offering genetic testing across multiple disease areas, now operating under Chapter 11 with restructured scope. Relevant as a historical molecular DNA diagnostics comparator despite current distress.
  • Exact Sciences: Exact Sciences is a major molecular diagnostics company best known for Cologuard, now expanding into multi-cancer detection and oncology. Relevant broad incumbent comparator for any molecular DNA diagnostics business.

Direct peers

  • Natera: Natera is a DNA-based diagnostics company specializing in cell-free DNA testing across reproductive health, oncology, and organ transplant monitoring. Closely comparable to MDNA given the molecular DNA focus and clinical diagnostic positioning.
  • NeoGenomics: NeoGenomics operates oncology-focused clinical laboratories providing molecular and genetic testing services to hospitals, oncologists, and researchers. Comparable as a direct molecular diagnostics services peer.
  • Veracyte: Veracyte is a genomic diagnostics company developing tests that resolve diagnostic ambiguity in cancer and other diseases using RNA and DNA-based methods. Direct comparator in genomic clinical diagnostics.

Emerging players

  • Personalis: Personalis is a smaller molecular diagnostics company focused on immuno-oncology and tumor molecular profiling. Comparable as a peer-scale molecular DNA diagnostics player with biopharma services revenue.
  • Caris Life Sciences: Caris provides molecular profiling services including DNA and RNA sequencing for oncology and biopharma partners. Comparable as a mid-sized molecular profiling peer with services + biopharma channel model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

MDNA Life Sciences social profiles

Digital presence

MDNA Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MDNA Life Sciences leadership team

Management profile

Number of profiles

Profiles5 records

MDNA Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MDNA Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MDNA Life Sciences

What does MDNA Life Sciences do?

MDNA Life Sciences is a biotechnology company developing molecular diagnostic products and biomarker discovery services centered on mitochondrial DNA (mtDNA) analysis. The firm applies proprietary genetic and molecular biology techniques to identify mtDNA-based biomarkers for disease detection and research applications, serving life sciences research and clinical diagnostic markets.

When was MDNA Life Sciences founded?

MDNA Life Sciences was founded in 2014. It employs 1 to 10 people.

Where is MDNA Life Sciences based?

MDNA Life Sciences is headquartered in West Palm Beach, United States, in the North America region.

Who are MDNA Life Sciences's main competitors?

Broad incumbents on record are Myriad Genetics, Guardant Health, Foundation Medicine, Invitae and Exact Sciences. Direct peers are Natera, NeoGenomics and Veracyte. Emerging players are Personalis and Caris Life Sciences.

Does MDNA Life Sciences have an API?

No public API is recorded for MDNA Life Sciences.

What industry is MDNA Life Sciences in?

MDNA Life Sciences's product category is Molecular Diagnostics and Biomarker Discovery. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at ApproximatelAditxt's subsidiary Pearsanta acquired MDNA Life Sciences' Mitomic platform for early disease and cancer detection. Consideration includes 50,000 Aditxt shares, warrants, $25 million preferred stock, and up to $3.2 million in transition payments. The deal aims to expand Pearsanta's diagnostic offerings in 2024 and beyond.Business Wire BlogAditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at ApproximatelAditxt, Inc. announced that its subsidiary, Pearsanta, Inc., has acquired MDNA Life Sciences Inc.’s proprietary Mitomic™ testing platform for early disease and cancer detection. The transaction involves $25 million in preferred stock, warrants, and potential transition service payments, expanding Pearsanta's portfolio with non-invasive diagnostic tests for conditions such as endometriosis and prostate cancer.Renaissance CapitalCancer diagnostics company MDNA Life Sciences ups deal size by 29% ahead of $13 million unit offeringMDNA Life Sciences raised its IPO deal size by 29% to $13 million, offering 2.6 million units at $4.13-$6.13. The company, developing mitochondrial DNA-based cancer and endometriosis tests, plans to list on Nasdaq under MDLS.Silicon RepublicNew blood test can detect debilitating female disease in almost all casesMDNA Life Sciences developed a blood test for endometriosis that detects the condition in 90% of cases, with results in days. The company plans to commercialize the test kit and expects regulatory approval within nine to 10 months. It also plans to release tests for ovarian and pancreatic cancers next year.PR NewswireMDNA Begins Global Roll-Out with Appointment of Distribution Partner in South KoreaMDNA Life Sciences Inc. has entered into an exclusive license agreement with BL&H, appointing the South Korean company as its first international commercial partner to distribute MDNA's Prostate Mitomic Test (PMT™) in South Korea. BL&H will validate the test in South Korea and market it as a more accurate alternative to the widely used but acknowledged-inaccurate PSA test for prostate cancer screening. The agreement represents MDNA's initial step in executing its global roll-out strategy to license Mitomic liquid biopsy tests to partners across multiple markets.PR NewswireProstate Core Mitomic Test™ Significantly Reduces Unnecessary Biopsies, Improves Cancer Detection, New Study Says.MDNA Life Sciences announced publication of clinical study findings in the peer-reviewed journal American Health & Drug Benefits, demonstrating that its Prostate Core Mitomic Test (PCMT™) reduced repeat biopsy rates 8-fold in men with negative test results and enabled earlier cancer detection in men with positive results. The study analyzed 1,467 men and confirmed the test's sensitivity of 85% and negative predictive value of 92%, matching prior case-control study results. The company intends to leverage this evidence to support Medicare reimbursement for the more than 23 million covered men and expand private payer coverage.PR NewswireMDNA Life Sciences Appoints New Management Team Members to Lead Development and Commercialization of Mitochondrial Diagnostic PipelineMDNA Life Sciences appointed Chris Mitton as CEO and Jack Riccardi as CFO, effective immediately. The company will launch two blood-based diagnostic tests for prostate cancer and endometriosis in 2016, while commercializing its Prostate Core Mitomic Test. The new team will focus on sales and product launches.PR NewswireMDNA Life Sciences Appoints New Management Team Members to Lead Development and Commercialization of Mitochondrial Diagnostic PipelineMDNA Life Sciences Inc. announced the appointment of Chris Mitton as Chief Executive Officer and Jack Riccardi as Chief Financial Officer, effective immediately, to strengthen the company's leadership as it prepares for key milestones in its mitochondrial DNA-based diagnostic pipeline. The new executive team will focus on commercializing the revenue-generating Prostate Core Mitomic Test and launching two blood-based diagnostic tests for prostate cancer and endometriosis in 2016. The appointments follow George Steinfels' tenure as interim CEO, during which he oversaw the acquisition of intellectual property and assets from Mitomics Inc.PR NewswireMDNA Life Sciences to Present at Biotech Showcase 2016MDNA Life Sciences Inc. announced it will present at the Biotech Showcase 2016 conference in San Francisco on January 12, 2016. The company will use the presentation to showcase its revenue-generating Prostate Core Mitomic Test and its pipeline of blood-based diagnostic tests for conditions including prostate cancer and endometriosis targeting launch in 2016. The presentation will highlight the company's mitochondrial DNA-based diagnostic platform for disease screening, diagnosis, prognosis, and monitoring.